1
|
Ballouhey Q, Panicker JN, Mazerolles C, Roumiguie M, Zaidi F, Rischmann P, Malavaud B, Game X. Sphingosine Kinase 1 urothelial expression is increased in patients with neurogenic detrusor overactivity. Int Braz J Urol 2016; 41:1141-7. [PMID: 26742972 PMCID: PMC4756940 DOI: 10.1590/s1677-5538.ibju.2014.0676] [Citation(s) in RCA: 6] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/30/2014] [Accepted: 05/04/2015] [Indexed: 01/28/2023] Open
Abstract
Objectives: To evaluate the expression of sphingosine kinase 1 (SPK1) in the bladder wall in patients with neurogenic lower urinary tract dysfunction and its association with clinical, urodynamic and pathological features. Materials and Methods: The expression of SPK1 was studied in bladder wall specimens obtained from cystectomy using immunohistochemistry in ten patients with spinal cord injury (n=8) or multiple sclerosis (n=2) with urodynamically proven neuropathic bladder dysfunction, and in controls (n=5). Inflammation and fibrosis were analysed with histological criteria and SPK1 expression was determined by individual immunohistochemical staining. Results: Significant increased SPK1 urothelial immunoreactivity was shown in patients compared to control group (p=0.03). By contrast, SPK1 immunoreactivity in patients was significantly decreased in the sub-urothelium, muscles and nerves, p=0.02; 0.01 and 0.003, respectively. Patients with neurogenic detrusor overactivity (NDO) had higher SPK1 urothelium expression than those without any DO (p=0.04). Conclusions: SPK1 is expressed in the human bladder wall, specifically the urothelium, in bladder specimens from patients with NDO. The role of SPK1 in the pathophysiology of NDO needs further elucidation.
Collapse
Affiliation(s)
| | - Jalesh N Panicker
- Department of Uro-Neurology, UCL Institute of Neurology, The National Hospital for Neurology and Neurosurgery, Queen Square, London, WC1N 3BG, United Kingdom
| | | | - Mathieu Roumiguie
- INSERM I2MC UMR1048, CHU Rangueil, Toulouse, France 1 Departement d'Urologie, CHU Rangueil, Toulouse, France
| | - Falek Zaidi
- Laboratoire d'Anatomo-pathologie, CHU Rangueil, Toulouse, France
| | - Pascal Rischmann
- Departement d'Urologie, CHU Rangueil, Toulouse, France.,INSERM I2MC UMR1048, CHU Rangueil, Toulouse, France 1 Departement d'Urologie, CHU Rangueil, Toulouse, France
| | - Bernard Malavaud
- Departement d'Urologie, CHU Rangueil, Toulouse, France.,INSERM I2MC UMR1048, CHU Rangueil, Toulouse, France 1 Departement d'Urologie, CHU Rangueil, Toulouse, France
| | - Xavier Game
- Departement d'Urologie, CHU Rangueil, Toulouse, France.,INSERM I2MC UMR1048, CHU Rangueil, Toulouse, France 1 Departement d'Urologie, CHU Rangueil, Toulouse, France
| |
Collapse
|